NovoCare Pharmacy Pricing in 2026: Every Dose, Every Condition, Every Expiry Date
NovoCare Pharmacy is Novo Nordisk's own direct self-pay channel. Read from its published price guide on 4 August 2026: the Wegovy pen is $349 a month at 0.25 to 2.4 mg, the HD 7.2 mg pen is $399, and the tablet is $149 at 1.5 and 4 mg rising to $299 at 9 and 25 mg. Two of those rates expire on stated dates.
The full ladder, as published
| Product and dose | Monthly | Condition |
|---|---|---|
| Tablet, 1.5 and 4 mg | $149 | 4 mg at this price only to 31 Aug 2026, then $199 |
| Tablet, 9 and 25 mg | $299 | Maintenance doses |
| Pen, new-patient intro | $199 | First two fills only, 0.25 or 0.5 mg, to 31 Dec 2026 |
| Pen, 0.25–2.4 mg | $349 | Standard self-pay |
| Wegovy HD 7.2 mg | $399 | Higher-dose pen |
| Ozempic, 0.25–1 mg | $349 | Self-pay |
| Ozempic, 2 mg | $499 | Self-pay |
| With commercial cover plus savings offer | $25 | Capped at $100/month in savings |
One month is defined as one box of four pens, or one bottle of thirty tablets.
Who NovoCare is for, and who it is not for
The savings offer beats the cash channel for anyone with commercial coverage — the cap is on the saving, not the price.
- Best fit: no coverage, or a plan that excludes weight-loss drugs. $349 against a roughly $1,349 retail list is the gap the programme exists to close.
- Not the best fit: commercial coverage that includes the drug. The savings offer commonly reaches $25, which is below the cash price.
- Excluded: Medicare and Medicaid beneficiaries are barred from the savings offer by federal law, and generally from the cash programme structured around it.
The $100 cap almost nobody mentions
The savings offer is described as "as little as $25", and the qualifier is a maximum saving of $100 a month. If your copay is $60, the offer takes you to $25. If your copay is $400, it takes you to $300, not $25. Both statements are true and only one of them is usually quoted.
How this compares with a compounded programme
The gap that made compounding the default answer to a cost question has narrowed sharply. At starter doses an approved tablet is $149 against roughly $145 for the cheapest compounded semaglutide we have seen — a difference of a few dollars between a product with a trial programme and one without. At a maintenance dose the approved tablet is $299, and the gap widens again.
Which comparison is the honest one depends entirely on the dose. Every published efficacy figure was collected at a maintenance dose.
How the cash channel changed the market
For most of 2023 and 2024 the comparison a cash-paying patient faced was a roughly $1,349 retail list price against a compounded programme at $99 to $200. That gap is the entire reason compounded GLP-1s became a mass market.
Manufacturer direct channels closed most of it. An approved tablet at $149 and a pen at $349 sit in a different relationship to a compounded programme than a $1,349 list price did, and the change happened in about eighteen months.
| Cash-pay brand | Cheapest compounded | Gap | |
|---|---|---|---|
| Through 2024 | ~$1,349 | ~$99–$200 | Very large |
| August 2026, starter dose | $149 tablet | ~$145 | A few dollars |
| August 2026, maintenance dose | $299 tablet | ~$145 | ~$154 |
Which row is the honest comparison depends on the dose. Every published efficacy figure was collected at a maintenance dose.
Reading any manufacturer price page properly
- Find the dose column. A single headline figure almost always describes one dose.
- Read the footnotes. That is where "first two fills" and expiry dates live.
- Check the definition of a month. Here it is one box of four pens or one bottle of thirty tablets.
- Check eligibility. Government beneficiaries are excluded from the savings offer.
- Note the cap. "As little as $25" is capped at $100 a month in savings.
What this page does not settle
- Whether you are eligible. That depends on your coverage and enrolment status.
- What happens after the stated expiry dates. The guide states the successor rates; whether they are extended is the manufacturer's decision.
- Pharmacy pickup versus home delivery pricing. The guide distinguishes them, and the figures here are the published self-pay rates.
What to do if you are on Medicare
Government beneficiaries are excluded from the manufacturer savings offer by federal law, and generally from the cash programme built around it. That exclusion is not a plan decision and cannot be appealed.
The separate route is the Medicare GLP-1 Bridge, a demonstration reported at around $50 a month for eligible Part D members, with prior authorisation. It has a scheduled end date, which makes it a different kind of arrangement from an ordinary benefit — worth confirming currency before relying on it.
| Route | Monthly | Twelve months | Who it is for |
|---|---|---|---|
| Commercial cover plus savings offer | $25 | $300 | Covered plans; capped at $100/mo saved |
| Medicare GLP-1 Bridge | $50 | $600 | Eligible Part D, with prior authorisation |
| Approved tablet, maintenance | $299 | $3,588 | No coverage, wants the approved oral route |
| Brand pen, self-pay | $349 | $4,188 | No coverage, wants the injection |
| Brand HD pen | $399 | $4,788 | Higher dose, prescriber-determined |
| Retail with no programme | ~$1,349 | ~$16,188 | Nobody, if a programme is available |
Read on the manufacturer's published price guide, 4 August 2026.
What this page does not settle
- Whether a compounded programme is cheaper for you. At a starter dose the gap is a few dollars; at maintenance it is around $154. The dose decides.
- Whether the expiring rates are extended. Two carry stated end dates.
- Your eligibility. Coverage type and enrolment status decide it, not this page.
Common questions
Is NovoCare the cheapest way to get Wegovy?
For someone with no coverage, it is the cheapest route to the brand: $349 against a roughly $1,349 retail list. For someone whose commercial plan covers the drug, the savings offer usually lands lower — frequently around $25 — so the cash channel is not the answer for that group.
Do I need a prescription?
Yes. NovoCare is a pharmacy, not a prescriber. Your clinician sends the prescription, or you take the savings offer to a participating pharmacy.
Why is the tablet cheaper than the pen?
At starter doses it is: $149 against $349. At maintenance doses the tablet is $299, which narrows the gap considerably. The two products also carry different requirements — the tablet is daily on an empty stomach, the pen is weekly with no food restriction.
What happens on 31 August 2026?
The 4 mg tablet moves from $149 to $199, per the published guide. The 1.5 mg dose stays at $149. Any page quoting a flat $149 after that date will be quoting a price that no longer exists for that dose, which is why we record the expiry alongside the figure.